Company / Working Capital
Idexx Laboratories Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$265.0M
FY2025
5-year range
-$134.3M / $543.7M
FY2021-FY2025
Trend
-20.2%
vs FY2024
Sector context
#101 of 165
Health Care
What the data says
At $265M, Idexx Laboratories's working capital ranks #101 of 165 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from -$134M in FY2022 to $544M in FY2023.
Based on SEC 10-K filings.
$265M in FY2025 with a 5-year CAGR of -11.2%.
Declined from $544M to $265M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -11.2%
- 10-Year CAGR
- -
Sector benchmark
#101 of 165 in Health CareTop 61% of 165This company $265.0M Sector average $814.4M
▼
-67.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.2%, indicating a declining trend.
- In FY2025, working capital decreased 20.2% year-over-year.
- Ranks #101 out of 165 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $265.0M | -20.2% |
| FY2024 | $332.0M | -38.9% |
| FY2023 | $543.7M | +504.8% |
| FY2022 | -$134.3M | -169.9% |
| FY2021 | $192.1M | -60.0% |
| FY2020 | $480.0M | +1150.3% |
| FY2019 | -$45.7M | +60.7% |
| FY2018 | -$116.3M | -256.9% |
| FY2017 | -$32.6M | +63.4% |
| FY2016 | -$89.0M | -153.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026